plerixafor has been researched along with Abnormalities, Autosome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azab, AK; Chatterjee, M; Decker, S; Duyster, J; Engelhardt, M; Follo, M; Ihorst, G; Lorenz, J; Müller, SJ; Simon, A; Waldschmidt, JM; Wäsch, R; Wider, D | 1 |
1 other study(ies) available for plerixafor and Abnormalities, Autosome
| Article | Year |
|---|---|
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aptamers, Nucleotide; Benzylamines; Biomarkers; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL12; Chromosome Aberrations; Coculture Techniques; Cyclams; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Immunophenotyping; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Phosphorylation; Protein Multimerization; Protein Transport; Receptors, CXCR; Stromal Cells | 2017 |